Holen Sie sich die Stockscreener-App
7.26
1.11%
0.08
Handel nachbörslich:
7.31
0.05
+0.69%
Schlusskurs vom Vortag:
$7.18
Offen:
$7.24
24-Stunden-Volumen:
1.01M
Relative Volume:
0.62
Marktkapitalisierung:
$553.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.09M
KGV:
-3.3456
EPS:
-2.17
Netto-Cashflow:
$-138.01M
1W Leistung:
-0.82%
1M Leistung:
-25.46%
6M Leistung:
-66.59%
1J Leistung:
-50.81%
1-Tages-Spanne:
$7.14
$7.32
1-Wochen-Bereich:
$6.98
$7.66
52-Wochen-Spanne:
$6.98
$24.17
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Vergleichen Sie KURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
7.26 | 553.07M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-14 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Assenagon Asset Management S.A. Has $7.88 Million Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
Assenagon Asset Management S.A. Sells 146,879 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Up 17.4% in December - MarketBeat
JPMorgan Chase & Co. Boosts Stake in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Harbor Capital Advisors Inc. Boosts Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology secures new headquarters in San Diego - Investing.com India
Kura Oncology secures new headquarters in San Diego By Investing.com - Investing.com Australia
Kura Oncology stock hits 52-week low at $8.38 amid market challenges - Investing.com Nigeria
Kura Oncology (NASDAQ:KURA) Sets New 12-Month LowTime to Sell? - MarketBeat
Brokers Set Expectations for Kura Oncology FY2029 Earnings - Defense World
Brokers Offer Predictions for Kura Oncology FY2029 Earnings - MarketBeat
BlackRock, Inc. Increases Stake in Kura Oncology Inc - GuruFocus.com
Long Term Trading Analysis for (KURA) - Stock Traders Daily
Scotiabank Cuts Kura Oncology (NASDAQ:KURA) Price Target to $10.00 - MarketBeat
Kura Oncology announces executive changes and settlement By Investing.com - Investing.com Australia
Kura Oncology announces executive changes and settlement - Investing.com India
Kura Oncology appoints new CMO and CSO By Investing.com - Investing.com Australia
Kura Oncology (NASDAQ:KURA) Sets New 1-Year LowTime to Sell? - MarketBeat
Kura Oncology Announces Leadership Changes and Appointments - MSN
Kura Oncology Promotes New Chief Medical Officer - MarketWatch
Kura Oncology appoints new CMO and CSO - Investing.com
Kura Oncology Announces Senior Executive Promotions - The Manila Times
Kura Oncology (NASDAQ:KURA) Hits New 12-Month LowHere's Why - MarketBeat
Kura Crashes 37% After $1.53 Billion Deal Slams The Door On A Takeover - MSN
Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of “Buy” by Analysts - Defense World
Objective long/short (KURA) Report - Stock Traders Daily
Kura Oncology (NASDAQ:KURA) Sets New 12-Month Low – Here’s What Happened - Defense World
Kura Oncology's Stock Sinks To US$8.94, But Insiders Sold Even Lower - Simply Wall St
Kura Oncology (NASDAQ:KURA) Reaches New 12-Month LowWhat's Next? - MarketBeat
Kura Oncology stock hits 52-week low at $8.83 amid market challenges - Investing.com Australia
Kura Oncology expands stock option plan - Investing.com India
Kura Oncology expands stock option plan By Investing.com - Investing.com UK
Kura Oncology (NASDAQ:KURA) Reaches New 52-Week LowWhat's Next? - MarketBeat
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade) (NASDAQ:KURA) - Seeking Alpha
(KURA) Proactive Strategies - Stock Traders Daily
Kura, Kyowa highlight positive combo data for ziftomenib - BioWorld Online
Kura Oncology's SWOT analysis: ziftomenib's promise buoys stock outlook By Investing.com - Investing.com UK
Kura Oncology's SWOT analysis: ziftomenib's promise drives stock outlook By Investing.com - Investing.com South Africa
Kura Oncology's SWOT analysis: ziftomenib's promise drives stock outlook - Investing.com India
Kura Oncology's SWOT analysis: ziftomenib's potential reshapes cancer stock landscape - Investing.com Canada
Kura Oncology’s (KURA) Overweight Rating Reaffirmed at Cantor Fitzgerald - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Call Transcript - MSN
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting - The Manila Times
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):